| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AAN: Donepezil showed to delay function decline in Alzheimer's By Richard Robinson Special to DG News
SAN DIEGO, CA -- May 5, 2000 -- Donepezil delays functional decline in patients with Alzheimer's disease, according to a study presented at the 52nd Annual Meeting of the American Academy of Neurology held here May 4, 2000. To test the effect of donepezil on activities of daily living (ADLs) in Alzheimer's disease (AD), Rachelle Doody, MD, of Baylor College of Medicine, in Houston, TX, and colleagues conducted a one-year, double-blind trial in 431 patients with mild-to-moderate AD. Patients received either placebo or 10 mg donepezil daily. The primary end-point was time to clinically evident functional decline, defined as follows: a decline in the ability to perform one or more ADLs present at baseline; a 20 per cent decline in the ability to perform instrumental ADLs; or an increase in the Clinical Dementia Rating over baseline of 1 or more points. Instrumental ADLs included use of the telephone, shopping, managing money, and other tasks beyond basic ADLs such as feeding and dressing. The median time to functional decline was 208 days for placebo and 357 days for donepezil (p=0.002). Loss of the ability to perform instrumental ADLs was the most common reason for reaching the endpoint. "At the last recorded visit, there was significantly less decline in functional ability in the treated group," said Dr. Doody. "By preserving functional ability in AD patients, treatment with donepezil should reduce caregiver burden," she said. The study was titled, "Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1- year placebo-controlled functional survival study."
Related Link: donepezil (Aricept).
|